CN1911231A - Medicine for treating burns - Google Patents
Medicine for treating burns Download PDFInfo
- Publication number
- CN1911231A CN1911231A CN 200610048160 CN200610048160A CN1911231A CN 1911231 A CN1911231 A CN 1911231A CN 200610048160 CN200610048160 CN 200610048160 CN 200610048160 A CN200610048160 A CN 200610048160A CN 1911231 A CN1911231 A CN 1911231A
- Authority
- CN
- China
- Prior art keywords
- medicine
- present
- examples
- burn
- medicated powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 7
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 16
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 229960003600 silver sulfadiazine Drugs 0.000 claims description 7
- 229930003270 Vitamin B Natural products 0.000 claims description 6
- 235000019156 vitamin B Nutrition 0.000 claims description 6
- 239000011720 vitamin B Substances 0.000 claims description 6
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 5
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 claims description 3
- 229960003640 mafenide Drugs 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 229960004306 sulfadiazine Drugs 0.000 claims description 2
- BRBKOPJOKNSWSG-UHFFFAOYSA-N sulfaguanidine Chemical compound NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1 BRBKOPJOKNSWSG-UHFFFAOYSA-N 0.000 claims description 2
- 229960004257 sulfaguanidine Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 150000003456 sulfonamides Chemical class 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 206010052428 Wound Diseases 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 13
- 230000000472 traumatic effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000009416 jing wan hong Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A medicine for treating burn with high curative effect and low cost is proportionally prepared from sulfonamides, borneol and VC.
Description
Technical field
The present invention relates to pharmaceutical product, specifically a kind of medicine that is used for the treatment of burn.
Technical background
Burn (comprising scald) is a kind of common sudden trauma, is all multifactor a kind of extremely complicated traumatic diseases that body causes that acts on such as physics, chemistry, radiation, and its sickness rate is the trend that rises year by year.Burn according to its order of severity can be divided into slightly, moderate, severe; According to the different levels of its local damage degree, with its three district's bands that are divided into similar concentric garden shape, promptly the center is the coagulation necrosis band, is the blood capillary blood stasis and stagnant zone on every side, and the periphery is congested band.The coagulation necrosis band is recoverability not, also claims the necrotic area band; Blood stasis and stagnant zone is the portion of tissue damage, belongs to " parabiosis " state; Congested band is the recoverability tissue; Blood stasis and stagnant zone and congested band change in organization mainly are that capillary permeability increases and expansion, slow blood flow, thus cause the blood capillary thromboembolism, cause local tissue hypoxia and cause influence the whole body system.Doctor trained in Western medicine generally adopts the dryness therapy when the treatment burn at present, promptly carries out dry exposed therapy at traumatic infection, allows wound surface keep dry, and breeds in a large number to suppress antibacterial; Stop traumatic infection simultaneously and with various antibiotic, impel the dry incrustation of wound surface; To the patient with severe symptoms, also need surgical operation to cut crust, skin-grafting.The problem that this method exists is: in simple dry the exposure, can cause the necrosis of human tissue cell; And the traumatic infection in the therapeutic process also is the problem that always allows the medical worker feel a delicacy about.Use penicillin as routine, can not reduce the early stage G-bacterium of burn patient cellulitis; And use 5～7 days persons of penicillin, can inspire drug-fast G-bacillus infection quickly.The application of medicine for external use such as silver sulfadiazine, mafenide, though traumatic infection is had significant control effect, its pair cell activity also has certain detrimental effect, particularly uses the silver sulfadiazine paste or the suspensoid of high concentration, and the suspicion that adds severely injured surface damage is arranged.Also having a kind of Therapeutic Method at present clinically is to adopt the external application occlusive dressing, promptly in wound surface coating Chinese medicinal ointment (as JINGWANHONG), antimicrobial ointment is wrapped up and be aided with the intravenous drip antibiotic.The shortcoming that this method exists is that Chinese medicinal ointment control infection ability can increase the weight of traumatic infection sometimes even also; And directly smearing of antimicrobial ointment can cause the bad or microcirculation disturbance of wound surface microcirculation, therefore can cause the generation of wound surface ulcer.Also there is a common problem in above method, be exactly the course of treatment long, the medical expense costliness.
Summary of the invention
Purpose of the present invention just provides a kind of good effect, fast, the low burn medicine of treatment cost of wound healing.
The object of the present invention is achieved like this:
Medicine provided by the present invention comprises the component of following weight part ratio:
5～8 parts in sulfanilamide medicated powder, 1～2 part of Borneolum Syntheticum, 1～2 part of vitamin c powder.
In the sulfa drugss such as the optional usefulness of sulfanilamide medicated powder bacteresulf, silver sulfadiazine, sulfadiazine, mafenide, sulfaguanidine any one is wherein with the silver sulfadiazine best results.
Also can be added with in the prescription of medicine of the present invention: vitamin B
21～2 part.Also can be added with vitamin B simultaneously
11～2 part.Can further improve the curative effect of wound healing like this.
Borneolum Syntheticum in the pharmaceutical formulation of the present invention has the effect of analgesia, removing the necrotic tissue and promoting granulation; Sulfa drugs is mainly used in the inhibition bacterial metabolism, so it has good control action to traumatic infection; Vitamin C is collagen and the necessary composition of intercellular substance, and it can promote wound healing.Borneolum Syntheticum, ascorbic adding have effectively overcome the infringement that sulfa drugs pair cell activity is caused.Three's 5 usefulness both can reduce oozing out of wound fluid, can quicken the healing of wound tissue again, also can avoid traumatic infection simultaneously; And wound surface has further been protected in the effect of the removing oxygen-derived free radicals that vitamin C had again.Therefore three medicines, 5 usefulness have good synergism, and its clinical manifestation is: patient's course of disease shortens greatly, and the healing wound surface does not have cicatrization.
Medicine of the present invention specifically has following characteristics:
(1) medicine traumatic infection control of the present invention is effective.All uses medicine person of the present invention does not all find secondary infection; The patient of existing traumatic infection before being admitted to hospital, the lighter's medication 2～3 days, original infection can be effectively controlled in heavy person's medication 7～8 days.
(2) medicine of the present invention can be combined into one rapidly with the exudate of wound surface, and retardance and improve blood stasis and stagnant zone and the pathophysiological change of congested band, impels the wound surface skin to be recovered as soon as possible and reaches physiological reparation state.So it is fast that it has wound healing, the effect that no spot tissue forms.After using medicine of the present invention,, save a large amount of medical expenses thereby can be the patient even III degree fire victim does not need to carry out dermatoplastic treatment more yet.
(3) medicine medicine-feeding no pain of the present invention is easy to use and cheap for manufacturing cost.
The beneficial effect of medicine of the present invention has obtained checking by following clinical trial.
Clinical data
497 examples 1.1 burn, male's 346 examples (accounting for 69.6%) wherein, women's 151 examples (accounting for 30.4%); The oldest 76 years old, minimum 9 months; The course of disease is the longest 1 month, the shortest 15 minutes.
1.2 the causative factors of injury boiled water is scalded 338 examples (accounting for 68%), oils 124 examples (accounting for 24.9%) of burning, and Colophonium is scalded 6 examples (accounting for 2%), other reason 29 examples (accounting for 5.8%) of burning.
1.3 burn surface area (calculating): 1%～8%318 example (accounting for 64%), 11%～56% 179 example (accounting for 36%) according to Chinese rule of Nine.
1.4 burn degree (with three degree quartering estimation depth of burns): I degree 119 examples (accounting for 24%), shallow II degree 124 examples (accounting for 25%), dark II 144 examples (accounting for 29%), III degree 110 examples (accounting for 22%).
Therapeutic Method:
At first clean wound surface, again medicated powder of the present invention is approached spreading on wound surface, adopt exposure method, every day 1-2 time with distilled water or normal saline.
As before using medicated powder of the present invention, when wound surface severe infections has taken place, need auxiliary intravenous drip antibiotic medicine 3～5 days.
Therapeutic outcome
Cure 472 examples, account for 95%, produce effects 23 examples account for 4.6%, and invalid 2 examples account for 0.4%, and shallow II degree was cured 242 examples in following 2～3 days, dark 4～6 days cure rate 140 examples of II degree, and the III degree was cured 99 examples in 9～20 days.
The fire victim uses ointments burn medicine behind burn, and uses medicine person of the present invention in 6 hours, is no cicatrix after healing and produces.None example of III degree fire victim adopts dermatoplastic treatment.
Preparation method of the present invention:
According to formula ratio, take by weighing sulfonamides medicated powder, vitamins medicated powder, add Borneolum Syntheticum, grind well and get final product.
Usage and dosage: behind distilled water or normal saline cleaning wound surface, sprinkle medicine of the present invention gently on wound surface, the medicated powder consumption is advisable with very thin flap coverage.Generally once a day.Too much as transudate, when causing the wound surface medicine to soak, can increase a drug.
The specific embodiment
The preparation embodiment of preparation of the present invention:
Embodiment 1:
Take by weighing silver sulfadiazine medicated powder 8kg, vitamin C medicated powder 1kg, vitamin B
1Medicated powder 1kg, vitamin B
2Medicated powder 1kg, mixing adds Borneolum Syntheticum 1kg again, grinds well, and is distributed into bag.
Following examples preparation method is identical with embodiment 1, and just drug component and consumption are different, but all have effect of the present invention.
Above embodiment all can realize effect of the present invention, and it is to further specify of the present invention, but can not constitute any qualification to the present invention.
Claims (5)
1, a kind of burn medicine is characterized in that it comprises the component of following weight part ratio:
5～8 parts in sulfanilamide medicated powder, 1～2 part of Borneolum Syntheticum, 1～2 part of vitamin c powder.
2, burn medicine according to claim 1 is characterized in that said sulfanilamide medicated powder is any one in bacteresulf, silver sulfadiazine, sulfadiazine, mafenide, the sulfaguanidine.
3, burn medicine according to claim 1 is characterized in that said sulfanilamide medicated powder is silver sulfadiazine.
4, burn medicine according to claim 1 and 2 is characterized in that it also contains vitamin B
21～2 part.
5, burn medicine according to claim 4 is characterized in that it also contains vitamin B
11～2 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100481609A CN100425238C (en) | 2006-08-18 | 2006-08-18 | Medicine for treating burns |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100481609A CN100425238C (en) | 2006-08-18 | 2006-08-18 | Medicine for treating burns |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1911231A true CN1911231A (en) | 2007-02-14 |
| CN100425238C CN100425238C (en) | 2008-10-15 |
Family
ID=37720395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100481609A Expired - Fee Related CN100425238C (en) | 2006-08-18 | 2006-08-18 | Medicine for treating burns |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100425238C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104324070A (en) * | 2014-11-03 | 2015-02-04 | 黄华良 | External and orally-taken drug for treating ulcer disease and preparation method of external and orally-taken drug |
| CN108042839A (en) * | 2017-12-19 | 2018-05-18 | 湖北工程学院 | A kind of chitosan complexes bandage and preparation method thereof |
| CN111920824A (en) * | 2020-09-11 | 2020-11-13 | 余朝权 | A Chinese medicinal composition for treating wound |
| CN114796288A (en) * | 2022-04-25 | 2022-07-29 | 吴彩芳 | External medicine for burns and scalds and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056303C (en) * | 1997-11-07 | 2000-09-13 | 伍先令 | Zaohuang paste and treating burns and its prepn. |
| CN1116048C (en) * | 2000-01-21 | 2003-07-30 | 卫和平 | External-use extract for treating burns and scalds fast and its preparation |
| CN1107510C (en) * | 2000-03-30 | 2003-05-07 | 蔡胜利 | Burn and scald treating medicine and its preparation |
-
2006
- 2006-08-18 CN CNB2006100481609A patent/CN100425238C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104324070A (en) * | 2014-11-03 | 2015-02-04 | 黄华良 | External and orally-taken drug for treating ulcer disease and preparation method of external and orally-taken drug |
| CN108042839A (en) * | 2017-12-19 | 2018-05-18 | 湖北工程学院 | A kind of chitosan complexes bandage and preparation method thereof |
| CN111920824A (en) * | 2020-09-11 | 2020-11-13 | 余朝权 | A Chinese medicinal composition for treating wound |
| CN114796288A (en) * | 2022-04-25 | 2022-07-29 | 吴彩芳 | External medicine for burns and scalds and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100425238C (en) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101066340B (en) | Compound externally applied tetrodotoxin ointment and its prepn | |
| CN103656092A (en) | Ointment for treating trauma and preparation method thereof | |
| CN103566071B (en) | Traditional Chinese medicine composition for treating ulcer and preparation method of powder of traditional Chinese medicine composition | |
| DE60207606T2 (en) | ARTICLES OF WOUND TREATMENT | |
| CN100425238C (en) | Medicine for treating burns | |
| CN105879006A (en) | Pharmaceutical composition for treating diabetic foot ulcer as well as preparation method and application of pharmaceutical composition | |
| CN1176709C (en) | Drug for curing scald, hrut and inflammations as well as hemorrhoids | |
| CN1058619C (en) | Antiphlogistic analgesic ointment for treating burn | |
| CN1183950C (en) | Chinese herbal medicine preparation for treating burns | |
| CN103690903B (en) | A kind of Chinese traditional compound medicine for the treatment of the injuries such as burn and scald decubital ulcer | |
| CN105030958A (en) | Pharmaceutical composition and application thereof | |
| CN1259098C (en) | Exterior-applied Chinese herbal medicine preparation for traumatic infection and inflammation-relieving acesodyne and its preparation method | |
| CN1186068C (en) | Externally applied Chinese medicine with functions of diminishing inflammation, promoting granulation, stopping itch and stopping pain and its prepn process | |
| CN1072499C (en) | External-use medicine for curing various chronic ulcers | |
| CN108392572B (en) | Plaster for removing stasis, promoting tissue regeneration, healing sore and relieving pain and preparation method and application thereof | |
| CN102688368B (en) | Traditional Chinese medicine for treating trauma hemostasis or telephium | |
| CN1258367C (en) | Medicine for treating trauma | |
| CN100370998C (en) | Chinese medicinal preparation for treating sore, and wound and turn and scald | |
| CN1088811A (en) | Medicinal liquid for treating tinea | |
| CN116327828B (en) | Lithospermum and peony seed oil spray film for light and medium burns and scalds and preparation method thereof | |
| CN103191163A (en) | Skin wound repairing pharmaceutical composition | |
| Anyakudo et al. | Comparative Wound Healing Effects of Honey, Olive Oil, Pawpaw Fruit Extract and Iodine in Diabetic Rats: an Evaluation and Prioritization of Potential Alternative Therapeutic Options | |
| CN101869578B (en) | External liniment for drawing pus out and diminishing inflammation | |
| CN100356926C (en) | Ointment medicine for treating bedsore | |
| CN1294915C (en) | Eliminating stasis and tissue generation toxic removing pill |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081015 Termination date: 20130818 |